444 related articles for article (PubMed ID: 24876152)
41. Transient PI3K inhibition induces apoptosis and overcomes HGF-mediated resistance to EGFR-TKIs in EGFR mutant lung cancer.
Donev IS; Wang W; Yamada T; Li Q; Takeuchi S; Matsumoto K; Yamori T; Nishioka Y; Sone S; Yano S
Clin Cancer Res; 2011 Apr; 17(8):2260-9. PubMed ID: 21220474
[TBL] [Abstract][Full Text] [Related]
42. Increase in hepatocyte growth factor receptor tyrosine kinase activity in renal carcinoma cells is associated with increased motility partly through phosphoinositide 3-kinase activation.
Nakamura T; Kanda S; Yamamoto K; Kohno T; Maeda K; Matsuyama T; Kanetake H
Oncogene; 2001 Nov; 20(52):7610-23. PubMed ID: 11753639
[TBL] [Abstract][Full Text] [Related]
43. Geldanamycins exquisitely inhibit HGF/SF-mediated tumor cell invasion.
Xie Q; Gao CF; Shinomiya N; Sausville E; Hay R; Gustafson M; Shen Y; Wenkert D; Vande Woude GF
Oncogene; 2005 May; 24(23):3697-707. PubMed ID: 15782129
[TBL] [Abstract][Full Text] [Related]
44. Targeting the C-MET/HGF Signaling Pathway in Pancreatic Ductal Adenocarcinoma.
Ghanaatgar-Kasbi S; Khorrami S; Avan A; Aledavoud SA; Ferns GA
Curr Pharm Des; 2018; 24(39):4619-4625. PubMed ID: 30636579
[TBL] [Abstract][Full Text] [Related]
45. Paracrine HGF/c-MET enhances the stem cell-like potential and glycolysis of pancreatic cancer cells via activation of YAP/HIF-1α.
Yan B; Jiang Z; Cheng L; Chen K; Zhou C; Sun L; Qian W; Li J; Cao J; Xu Q; Ma Q; Lei J
Exp Cell Res; 2018 Oct; 371(1):63-71. PubMed ID: 30056064
[TBL] [Abstract][Full Text] [Related]
46. Regulation of hepatocyte growth factor-mediated urokinase plasminogen activator secretion by MEK/ERK activation in human stomach cancer cell lines.
Lee KH; Choi EY; Kim MK; Hyun MS; Jang BI; Kim TN; Kim SW; Song SK; Kim JH; Kim JR
Exp Mol Med; 2006 Feb; 38(1):27-35. PubMed ID: 16520550
[TBL] [Abstract][Full Text] [Related]
47. Hepatocyte growth factor is a survival factor for endothelial cells and is expressed in human atherosclerotic plaques.
Ma H; Calderon TM; Fallon JT; Berman JW
Atherosclerosis; 2002 Sep; 164(1):79-87. PubMed ID: 12119196
[TBL] [Abstract][Full Text] [Related]
48. Angiostatin selectively inhibits signaling by hepatocyte growth factor in endothelial and smooth muscle cells.
Wajih N; Sane DC
Blood; 2003 Mar; 101(5):1857-63. PubMed ID: 12406896
[TBL] [Abstract][Full Text] [Related]
49. Cross-talk between the VEGF-A and HGF signalling pathways in endothelial cells.
Sulpice E; Ding S; Muscatelli-Groux B; Bergé M; Han ZC; Plouet J; Tobelem G; Merkulova-Rainon T
Biol Cell; 2009 Sep; 101(9):525-39. PubMed ID: 19281453
[TBL] [Abstract][Full Text] [Related]
50. Hepatocyte growth factor/Met system promotes endometrial and endometriotic stromal cell invasion via autocrine and paracrine pathways.
Yoshida S; Harada T; Mitsunari M; Iwabe T; Sakamoto Y; Tsukihara S; Iba Y; Horie S; Terakawa N
J Clin Endocrinol Metab; 2004 Feb; 89(2):823-32. PubMed ID: 14764801
[TBL] [Abstract][Full Text] [Related]
51. Hepatocyte growth factor/c-met signaling in regulating urokinase plasminogen activator in human stomach cancer: A potential therapeutic target for human stomach cancer.
Lee KH; Choi EY; Hyun MS; Jang BI; Kim TN; Kim SW; Song SK; Kim JH; Kim JR
Korean J Intern Med; 2006 Mar; 21(1):20-7. PubMed ID: 16646560
[TBL] [Abstract][Full Text] [Related]
52. Cellular and molecular mechanisms of HGF/Met in the cardiovascular system.
Gallo S; Sala V; Gatti S; Crepaldi T
Clin Sci (Lond); 2015 Dec; 129(12):1173-93. PubMed ID: 26561593
[TBL] [Abstract][Full Text] [Related]
53. Boswellia frereana suppresses HGF-mediated breast cancer cell invasion and migration through inhibition of c-Met signalling.
Parr C; Ali AY
J Transl Med; 2018 Oct; 16(1):281. PubMed ID: 30314527
[TBL] [Abstract][Full Text] [Related]
54. Analogs of the hepatocyte growth factor and macrophage-stimulating protein hinge regions act as Met and Ron dual inhibitors in pancreatic cancer cells.
Church KJ; Vanderwerff BR; Riggers RR; McMicheal MD; Mateo-Victoriano B; Sukumar SR; Harding JW
Anticancer Drugs; 2016 Sep; 27(8):766-79. PubMed ID: 27314431
[TBL] [Abstract][Full Text] [Related]
55. Invasion-Metastasis by Hepatocyte Growth Factor/c-Met Signaling Concomitant with Induction of Urokinase Plasminogen Activator in Human Pancreatic Cancer: Role as Therapeutic Target.
Lee KH; Hyun MS; Kim JR
Cancer Res Treat; 2003 Jun; 35(3):207-12. PubMed ID: 26680937
[TBL] [Abstract][Full Text] [Related]
56. Targeting the HGF/c-MET pathway in advanced pancreatic cancer: a key element of treatment that limits primary tumour growth and eliminates metastasis.
Xu Z; Pang TCY; Liu AC; Pothula SP; Mekapogu AR; Perera CJ; Murakami T; Goldstein D; Pirola RC; Wilson JS; Apte MV
Br J Cancer; 2020 May; 122(10):1486-1495. PubMed ID: 32203220
[TBL] [Abstract][Full Text] [Related]
57. MET/HGF Co-Targeting in Pancreatic Cancer: A Tool to Provide Insight into the Tumor/Stroma Crosstalk.
Modica C; Tortarolo D; Comoglio PM; Basilico C; Vigna E
Int J Mol Sci; 2018 Dec; 19(12):. PubMed ID: 30544501
[TBL] [Abstract][Full Text] [Related]
58. CAF-derived HGF promotes cell proliferation and drug resistance by up-regulating the c-Met/PI3K/Akt and GRP78 signalling in ovarian cancer cells.
Deying W; Feng G; Shumei L; Hui Z; Ming L; Hongqing W
Biosci Rep; 2017 Apr; 37(2):. PubMed ID: 28258248
[TBL] [Abstract][Full Text] [Related]
59. Silencing of MUC20 suppresses the malignant character of pancreatic ductal adenocarcinoma cells through inhibition of the HGF/MET pathway.
Chen ST; Kuo TC; Liao YY; Lin MC; Tien YW; Huang MC
Oncogene; 2018 Nov; 37(46):6041-6053. PubMed ID: 29993037
[TBL] [Abstract][Full Text] [Related]
60. Simultaneous up-regulation of urokinase-type plasminogen activator (uPA) and uPA receptor by hepatocyte growth factor/scatter factor in human glioma cells.
Moriyama T; Kataoka H; Hamasuna R; Yoshida E; Sameshima T; Iseda T; Yokogami K; Nakano S; Koono M; Wakisaka S
Clin Exp Metastasis; 1999; 17(10):873-9. PubMed ID: 11089886
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
